Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease

被引:73
作者
Fontana, S [1 ]
Gerritsen, HE [1 ]
Hovinga, JK [1 ]
Furlan, M [1 ]
Lämmle, B [1 ]
机构
[1] Univ Hosp Bern, Inselspital, Cent Haematol Lab, CH-3010 Bern, Switzerland
关键词
microangiopathy; neoplasia; von Willebrand factor; proteolysis;
D O I
10.1046/j.1365-2141.2001.02704.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Complete deficiency of von Willebrand factor-cleaving protease (VWF-cp) has recently been identified as a pathogenetically important factor for thrombotic thrombocytopenic purpura (TTP). Microangiopathic haemolytic anaemia (MAHA) with thrombocytopenia in patients with metastasizing neoplasms is clinically similar to TTP, however, the pathogenesis of the condition is unclear. Partial deficiency of VWF-cp in metastasizing malignancy has recently been reported in patients without MAHA, Our study shows normal or subnormal VWF-cp activity in four patients with metastasizing neoplasia-associated MAHA but, in contrast to classical TTP, no complete deficiency of VWF-cp despite the full clinical picture of MAHA.
引用
收藏
页码:100 / 102
页数:3
相关论文
共 12 条
[1]   CARCINOMA-ASSOCIATED HEMOLYTIC-UREMIC SYNDROME - A COMPLICATION OF MITOMYCIN-C CHEMOTHERAPY [J].
CANTRELL, JE ;
PHILLIPS, TM ;
SCHEIN, PS .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (05) :723-734
[2]  
Fisher DC, 1996, BONE MARROW TRANSPL, V18, P193
[3]   Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura [J].
Furlan, M ;
Robles, R ;
Solenthaler, M ;
Wassmer, M ;
Sandoz, P ;
Lammle, B .
BLOOD, 1997, 89 (09) :3097-3103
[4]   Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura [J].
Furlan, M ;
Robles, R ;
Solenthaler, M ;
Lämmle, B .
BLOOD, 1998, 91 (08) :2839-2846
[5]   Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome [J].
Furlan, M ;
Robles, R ;
Galbusera, M ;
Remuzzi, G ;
Kyrle, PA ;
Brenner, B ;
Krause, M ;
Scharrer, I ;
Aumann, V ;
Mittler, U ;
Solenthaler, M ;
Lämmle, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (22) :1578-1584
[6]  
Gerritsen HE, 1999, THROMB HAEMOSTASIS, V82, P1386
[7]   Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura hemolytic uremic syndrome in the cancer patient [J].
Gordon, LI ;
Kwaan, HC .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1999, 25 (02) :217-221
[8]   Thrombotic thrombocytopenic purpura: Understanding a disease no longer rare [J].
Moake, JL ;
Chow, TW .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1998, 316 (02) :105-119
[9]   A TOXIC INTERACTION BETWEEN MITOMYCIN-C AND TAMOXIFEN CAUSING THE HEMOLYTIC-UREMIC SYNDROME [J].
MONTES, A ;
POWLES, TJ ;
OBRIEN, MER ;
ASHLEY, SE ;
LUCKIT, J ;
TRELEAVEN, J .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (13) :1854-1857
[10]   CALPAIN PROTEOLYSIS OF VONWILLEBRAND-FACTOR ENHANCES ITS BINDING TO PLATELET MEMBRANE GLYCOPROTEIN IIB/IIIA - AN EXPLANATION FOR PLATELET-AGGREGATION IN THROMBOTIC THROMBOCYTOPENIC PURPURA [J].
MOORE, JC ;
MURPHY, WG ;
KELTON, JG .
BRITISH JOURNAL OF HAEMATOLOGY, 1990, 74 (04) :457-464